MedWatch

Ambu benefits from new FDA warnings: "The most positive news for Ambu this year"

FDA's warning about higher-than-expected danger of infection with reprocessed duodenoscopes is amazing news for Danish medtech group Ambu, according to analysts. CEO Lars Marcher says that the company is working flat out to obtain approval of its equipment.

Foto: /Ritzau Scanpix/Claus Bech

New interim results from an FDA surveillance study have boosted Danish company Ambu's share price.

FDA warns about higher-than-expected contamination rates with reprocessed duodenoscopes, and that is grist to Ambu's mill.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier